Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6049711 | 0.89 | P2RX7 (0.53) | P2RX7AVPR1A | |
| Hydrochloric Acid SCHEMBL5960226 | 0.88 | P2RX7 (0.52) | P2RX7AVPR1A | |
| SCHEMBL7568653 | 0.83 | P2RX7 (0.70) | P2RX7 | |
| SCHEMBL7659100 | 0.80 | P2RX7 (0.72) | P2RX7AVPR1A | |
| SCHEMBL7666336 | 0.79 | P2RX7 (0.69) | P2RX7AVPR1A | |
| SCHEMBL7660333 | 0.79 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL5430891 | 0.78 | P2RX7 (0.62) | P2RX7 | |
| SCHEMBL7663447 | 0.78 | P2RX7 (0.70) | P2RX7AVPR1A | |
| SCHEMBL5077430 | 0.78 | P2RX7 (1.00) | P2RX7AVPR1A | |
| SCHEMBL5435569 | 0.78 | P2RX7 (0.41) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207577-A1 | Mixture of a P2X7 (purinergic) receptor antagonist, and a corticosteroid; 1-adamantylalkylamide derivatives with benzyl or pyridyl group; respiratory system disorders, chronic obstructive pulmonary disease; antiasthmatics; formoterol, budesonide; kits | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | claimed |
| US-20070281931-A1 | Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | US | claimed |
| US-20070082930-A1 | Pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti-inflammatory drug | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | US | claimed |
| US-20070032465-A1 | Pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | claimed |
| US-20070010497-A1 | Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | claimed |
| US-20060247257-A1 | Combination | ASTRAZENECA AB (SE) | 2006-11-02 | — | — | US | claimed |
| US-6492355-B1 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2002-12-10 | — | — | US | claimed |
| US-20130195919-A1 | INDUCED DENDRITIC CELL COMPOSITIONS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2013036296-A1 | COMPOSITIONS AND METHODS FOR PRODUCING ANTIGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS WITH SYNTHETIC NANOCARRIERS | SELECTA BIOSCIENCES, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013036294-A1 | ANTIGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE CYTOTOXIC T LYMPHOCYTE RESPONSES | SELECTA BIOSCIENCES, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013036303-A2 | INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE SYSTEMIC INFLAMMATORY CYTOKINES | SELECTA BIOSCIENCES, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013036297-A1 | THERAPEUTIC PROTEIN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS AND METHODS OF USE | SELECTA BIOSCIENCES, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013036295-A1 | ANTIGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE ANTIBODY RESPONSES | SELECTA BIOSCIENCES, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| US-20080207577-A1 | Mixture of a P2X7 (purinergic) receptor antagonist, and a corticosteroid; 1-adamantylalkylamide derivatives with benzyl or pyridyl group; respiratory system disorders, chronic obstructive pulmonary disease; antiasthmatics; formoterol, budesonide; kits | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-20070281931-A1 | Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | US | disclosed |
| US-20070082930-A1 | Pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti-inflammatory drug | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | US | disclosed |
| US-20070032465-A1 | Pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| US-20070010497-A1 | Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| US-20060247257-A1 | Combination | ASTRAZENECA AB (SE) | 2006-11-02 | — | — | US | disclosed |
| US-6492355-B1 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281931-A1 | Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate | P2RX7, P2RY1, P2RX5 | P2RX7 1/4885AVPR1A 1914/4885 |
| US-20070010497-A1 | Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine | P2RX7, P2RX5, P2RX2 | P2RX7 1/4885AVPR1A 2989/4885 |
| US-20070082930-A1 | Pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti-inflammatory drug | P2RX7, P2RX3, P2RX5 | P2RX7 1/4885AVPR1A 1626/4885 |
| US-20060247257-A1 | Combination | P2RX7, PCSK9, P2RX1 | P2RX7 1/4885AVPR1A 1340/4885 |
| US-20080207577-A1 | Mixture of a P2X7 (purinergic) receptor antagonist, and a corticosteroid; 1-adamantylalkylamide derivatives with benzyl or pyridyl group; respiratory system disorders, chronic obstructive pulmonary disease; antiasthmatics; formoterol, budesonide; kits | P2RY1, P2RX3, P2RX7 | P2RX7 3/4885AVPR1A 943/4885 |
| US-20070032465-A1 | Pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha | P2RX7, P2RX1, P2RX5 | P2RX7 1/4885AVPR1A 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.